CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Cardiobase
Xagena Salute

Search results for "Multaq"

The FDA ( Food and Drug Administration ) has completed a safety review of Multaq ( Dronedarone ). This review showed that Multaq increased the risk of serious cardiovascular events, including death, w ...


Dronedarone ( Multaq ) is a non-iodinated benzofuran derivative with antiarrhythmic properties. In placebo-controlled atrial fibrillation ( AF ) trials, the drug was found to have divergent effects on ...


Dronedarone ( Multaq ) is an Amiodarone analog that differs structurally from Amiodarone in that the iodine moiety was removed and a methane-sulfonyl group was added. These modifications reduce thyr ...


The aim of a study was to examine mortality and liver disease among patients exposed to Dronedarone ( Multaq ).There has been concern about the safety of Dronedarone, especially for patients with hear ...


Dronedarone ( Multaq ) is a new antiarrhythmic drug used in the treatment of atrial fibrillation ( AF ). Researchers at Feinberg School of Medicine, Northwestern University ( Chicago, USA ) have inves ...


A study has assessed safety and cardiovascular outcomes of Dronedarone ( Multaq ) in patients with paroxysmal or persistent atrial fibrillation ( AF ) with coronary heart disease ( CHD ). Coronary h ...


Dronedarone ( Multaq ) is a non-iodinated benzofuran derivative with antiarrhythmic properties. In placebo-controlled atrial fibrillation trials, the drug was found to have divergent effects on endpoi ...


Elevated serum Digoxin concentration can cause toxicity, including death. Dronedarone ( Multaq ) increases Digoxin concentration by P-glycoprotein interaction. In PALLAS ( Permanent Atrial Fibrillat ...


Little is known in clinical practice about antiarrhythmic drugs ( AADs ) use in patients with atrial fibrillation ( particularly younger ones ) who do not have structural heart disease. Using the ...


Dronedarone ( Multaq ) is a benzofuran derivative with a pharmacological profile similar to Amiodarone but has a more rapid onset of action and a much shorter half-life ( 13-19 h ). Researchers ha ...


Although there are many different antiarrhythmic drugs approved for rhythm management of atrial fibrillation, little comparative effectiveness data exist to guide drug selection. Researchers follow ...